Access the full text.
Sign up today, get DeepDyve free for 14 days.
D. Blackman, J. Morris-Thurgood, J. Atherton, G. Ellis, R. Anderson, J. Cockcroft, M. Frenneaux (2000)
Endothelium-derived nitric oxide contributes to the regulation of venous tone in humans.Circulation, 101 2
G. Viberti, S. Kahn, D. Greene, W. Herman, B. Zinman, R. Holman, S. Haffner, Daniel Levy, J. Lachin, Rhona Berry, M. Heise, N. Jones, M. Freed (2002)
A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes.Diabetes care, 25 10
M. Stearne, S. Palmer, M. Hammersley, S. Franklin, R. Spivey, J. Levy, C. Tidy, N. Bell, J. Steemson, B. Barrow, R. Coster, K. Waring, J. Nolan, E. Truscott, N. Walravens, L. Cook, H. Lampard, C. Merle, P. Parker, J. Mcvittie, I. Draisey, L. Murchison, A. Brunt, M. Williams, D. Pearson, X. Petrie, M. Lean, D. Walmsley, M. Lyall, E. Christie, J. Church, E. Thomson, A. Farrow, J. Stowers, M. Stowers, K. McHardy, N. Patterson, A. Wright, N. Levi, A. Shearer, R. Thompson, G. Taylor, S. Rayton, M. Bradbury, A. Glover, A. Smyth-Osbourne, C. Parkes, J. Graham, P. England, S. Gyde, C. Eagle, B. Chakrabarti, J. Smith, J. Sherwell, E. Kohner, A. Dornhurst, M. Doddridge, M. Dumskyj, S. Walji, P. Sharp, M. Sleightholm, G. Vanterpool, C. Rose, G. Frost, M. Roseblade, S. Elliott, S. Forrester, M. Foster, K. Myers, R. Chapman, J. Hayes, R. Henry, M. Featherston, G. Archbold, M. Copeland, R. Harper, I. Richardson, S. Martín, H. Davison, D. Hadden, L. Kennedy, A. Atkinson, A. Culbert, C. Hegan, H. Tennet, N. Webb, I. Robinson, J. Holmes, P. Bell, D. McCance, J. Rutherford, S. Nesbitt, A. Spathis, S. Hyer, M. Nanson, L. James, J. Tyrell, C. Davis, P. Strugnell, M. Booth, H. Petrie, D. Clark, B. Rice, S. Hulland, J. Barron, J. Yudkin, B. Gould, J. Singer, A. Badenock, M. Eckert, K. Alibhai, E. Marriot, C. Cox, R. Price, M. Fernandez, A. Ryle, S. Clarke, G. Wallace, E. Mehmed, S. Macfarlane, R. Greenwood, J. Wilson, M. Denholm, R. Temple, K. Whitfield, F. Johnson, C. Munroe, S. Gorick, E. Duckworth, M. Flatman, S. Rainbow, L. Borthwick, D. Wheatcroft, R. Seaman, R. Christie, W. Wheatcroft, P. Musk, J. White, S. McDougal, M. Bond, P. Raniga, R. Newton, R. Jung, C. Roxburgh, B. Kilgallon, L. Dick, N. Waugh, S. Kilby, A. Ellingford, J. Burns, C. Fox, M. Holloway, H. Coghill, N. Hein, A. Fox, W. Cowan, M. Richard, K. Quested, S. Evans, R. Paisey, N. Brown, A. Tucker, R. Paisey, F. Garrett, J. Hogg, P. Park, K. Williams, Philip Harvey, R. Wilcocks, S. Mason, J. Frost, C. Warren, P. Rocket, L. Bower, J. Roland, D. Brown, J. Youens, K. Stanton-King, H. Mungall, W. Maddison, D. Donnelly, S. King, P. Griffin, S. Smith, S. Church, G. Dunn, Apr Wilson, K. Palmer, P. Brown, D. Humphriss, A. Davidson, R. Rose, L. Armistead, S. Townsend, P. Poon, I. Peacock, N. Culverwell, M. Charlton, B. Connolly, J. Peacock, J. Barrett, J. Wain, W. Beeston, G. King, P. Hill, A. Boulton, A. Robertson, Katoulis, A. Olukoga, H. McDonald, S. Kumar, F. Abouaesha, B. Abuaisha, E. Knowles, S. Higgins, J. Booker, J. Sunter, K. Breislin, R. Parker, P. Raval, J. Curwell, H. Davenport, G. Shawcross, A. Prest, J. Grey, H. Cole, C. Sereviratne, R. Young, T. Dornan, J. Clyne, M. Gibson, I. O'Connell, L. Wong, S. Wilson, K. Wright, C. Wallace, D. McDowell, A. Burden, E. Sellén, R. Gregory, M. Roshan, N. Vaghela, M. Burden, C. Sherriff, J. Clarke, J. Grenfell, J. Tooke, K. Macleod, C. Searnark, M. Rammell, C. Pym, J. Stockman, C. Yeo, J. Piper, L. Leighton, E. Green, M. Hoyle, K. Jones, A. Hudson, A. James, A. Shore, A. Higham, B. Martin (1998)
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38BMJ, 317
H. Ghanim, R. Garg, A. Aljada, P. Mohanty, Y. Kumbkarni, E. Assian, Wael Hamouda, P. Dandona (2001)
Suppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese.The Journal of clinical endocrinology and metabolism, 86 3
K.S.L. Lam, S.C. Tiu, M.W. Tsang (1998)
Acarbose in NIDDM patients with poor control on conventional oral agentsDiabetes Care, 21
Mehmood Khan, J. Peter, J. Xue (2002)
A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone.Diabetes care, 25 4
J. Chan, Kin-Wei Chan, L. Ho, Martin Fuh, Lee Horn, R. Sheaves, A. Panelo, Duk-Kyu Kim, Mustaffa Embong (1998)
An Asian Multicenter Clinical Trial to Assess the Efficacy and Tolerability of Acarbose Compared With Placebo in Type 2 Diabetic Patients Previously Treated With DietDiabetes Care, 21
S. Haffner, S. Lehto, T. Rönnemaa, K. Pyörälä, M. Laakso (1998)
Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.The New England journal of medicine, 339 4
A. Caballero, R. Saouaf, S. Lim, O. Hamdy, K. Abou-Elenin, Colleen O’Connor, F. Logerfo, E. Horton, A. Veves (2003)
The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial.Metabolism: clinical and experimental, 52 2
Michel Marre, L. Gaal, K. Usadel, M. Ball, I. Whatmough, C. Guitard (2002)
Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patientsDiabetes, 4
M. Pyörälä, H. Miettinen, M. Laakso, Kalevi rälä (1998)
Hyperinsulinemia predicts coronary heart disease risk in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study.Circulation, 98 5
A. Festa, R. D'Agostino, G. Howard, L. Mykkänen, R. Tracy, S. Haffner (2000)
Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS).Circulation, 102 1
P. Mohanty, A. Aljada, H. Ghanim (2001)
Rosiglitazone improves vascular reactivity, inhibits reactive oxygen species (ROS) generation, reduces p47phox subunit expression in mononuclear cells (MNC) and reduces C reactive protein (CRP) and monocyte chemotactic protein-1 (MCP-1): evidence of a potent anti-inflammatory effect [abstract no. 276-OR]Diabetes, 50
M. Freed, R. Ratner, S. Marcovina, M. Kreider, N. Biswas, B. Cohen, J. Brunzell (2002)
Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus.The American journal of cardiology, 90 9
P. Johnston, P. Feig, R. Coniff, A. Krol, D. Kelley, A. Mooradian (1998)
Chronic Treatment of African-American Type 2 Diabetic Patients With β-Glucosidase InhibitionDiabetes Care, 21
Neelima Chu, A. Kong, Dennis Kim, D. Armstrong, S. Baxi, R. Deutsch, M. Caulfield, S. Mudaliar, R. Reitz, R. Henry, P. Reaven (2002)
Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes.Diabetes care, 25 3
D. Simonson (1988)
Etiology and Prevalence of Hypertension in Diabetic PatientsDiabetes Care, 11
F. Ovalle, D.S.H. Bell (1999)
Troglitazone’s effect on lipoprotein (a) levels [letter]Diabetes Care, 22
C. Tack, P. Smits, P. Demacker, A. Stalenhoef (1998)
Troglitazone Decreases the Proportion of Small, Dense LDL and Increases the Resistance of LDL to Oxidation in Obese SubjectsDiabetes Care, 21
J. Meigs, M. Mittleman, D. Nathan, G. Tofler, Daniel Singer, Patricia Murphy-Sheehy, I. Lipińska, R. D’Agostino, P. Wilson (2000)
Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study.JAMA, 283 2
R.A. DeFronzo, A.M. Goodman (1995)
Efficacy of metformin in patients with non-insulin-dependent diabetes mellitusN Engl J Med, 333
Mayer Davidson (1995)
Clinical implications of insulin resistance syndromes.The American journal of medicine, 99 4
T. Ogihara, H. Rakugi, H. Ikegami, H. Mikami, K. Masuo (1995)
Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives.American journal of hypertension, 8 3
C. Gaboury, D. Simonson, E. Seely, N. Hollenberg, G. Williams (1994)
Relation of pressor responsiveness to angiotensin II and insulin resistance in hypertension.The Journal of clinical investigation, 94 6
E. Diamanti-Kandarakis, Giovanna Spina, C. Kouli, Ilias Migdalis (2001)
Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy.The Journal of clinical endocrinology and metabolism, 86 10
Ken Kato, H. Satoh, Y. Endo, D. Yamada, S. Midorikawa, W. Sato, Kenji Mizuno, T. Fujita, K. Tsukamoto, Tsuyoshi Watanabe (1999)
Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: A possible role for PPARgamma in endothelial function.Biochemical and biophysical research communications, 258 2
J.C.N. Chan, K.A. Chan, L.L.T. Ho (1998)
An Asian multicenter clinical trial to assess the efficacy and tolerability of acarbose compared with placebo in type 2 diabetic patients previously treated with diet: the Asian Acarbose Study GroupDiabetes Care, 21
S. Haffner, A. Greenberg, W. Weston, Hongzi Chen, K. Williams, M. Freed (2002)
Effect of Rosiglitazone Treatment on Nontraditional Markers of Cardiovascular Disease in Patients With Type 2 Diabetes MellitusCirculation: Journal of the American Heart Association, 106
T. Ishizuka, S. Itaya, H. Wada, M. Ishizawa, M. Kimura, K. Kajita, Y. Kanoh, A. Miura, N. Muto, K. Yasuda (1998)
Differential effect of the antidiabetic thiazolidinediones troglitazone and pioglitazone on human platelet aggregation mechanism.Diabetes, 47 9
H. Hirose, T. Kawai, Yukihiro Yamamoto, M. Taniyama, M. Tomita, K. Matsubara, Y. Okazaki, T. Ishii, Y. Oguma, I. Takei, T. Saruta (2002)
Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes.Metabolism: clinical and experimental, 51 3
T. Kawamura, G. Egusa, R. Fujikawa, Takehiko Watanabe, K. Oda, S. Kataoka, S. Takayama, K. Kubo, Shinichi Yamamoto, K. Noma, R. Orita, M. Yamakido (1998)
Effect of acarbose on glycemic control and lipid metabolism in patients with non—insulin-dependent diabetes mellitusCurrent Therapeutic Research-clinical and Experimental, 59
T. Marbury, Won-Chin Huang, P. Strange, H. Lebovitz (1999)
Repaglinide versus glyburide: a one-year comparison trial.Diabetes research and clinical practice, 43 3
J. Reusch (2002)
Current concepts in insulin resistance, type 2 diabetes mellitus, and the metabolic syndrome.The American journal of cardiology, 90 5A
Antonio Ceriello, Nadia Bortolotti, E. Motz, Carlo Pieri, Michele Marra, L. Tonutti, S. Lizzio, Fabiola Feletto, B. Catone, C. Taboga (1999)
Meal-induced oxidative stress and low-density lipoprotein oxidation in diabetes: the possible role of hyperglycemia.Metabolism: clinical and experimental, 48 12
'. Rosenstock, '. Deinhorn, '. Khershon, N. Glazer, PlwrmD, Y. S (2002)
EFFICACY AND SAFETY OF PIOGLITAZONE IN TYPE 2 DIABETES: A RANDOMISED, PLACEBO‐CONTROLLED STUDY IN PATIENTS RECEIVING STABLE INSULIN THERAPYInternational Journal of Clinical Practice, 56
Russel Scott, C. Lintott, P. Zimmet, L. Campbell, K. Bowen, T. Welborn (1999)
Will acarbose improve the metabolic abnormalities of insulin-resistant type 2 diabetes mellitus?Diabetes research and clinical practice, 43 3
H.E. Lebovitz, J.F. Dole, R. Patwardhan (2001)
Rosiglitazone monotherapy is effective in patients with type 2 diabetes: the Rosiglitazone Clinical Trials Study Group. [published erratum appears in J Clin Endocrinol Metab 2001 Apr; 86 (4): 1659]J Clin Endocrinol Metab, 86
N. Amador-Licona, J. Guízar-Mendoza, E. Vargas, G. Sánchez-Camargo, L. Zamora-Mata (2000)
The Short-Term Effect of a Switch from Glybenclamide to Metformin on Blood Pressure and Microalbuminuria in Patients with Type 2 Diabetes MellitusArchives of Medical Research, 31
T. Temelkova-Kurktschiev, G. Siegert, S. Bergmann, E. Henkel, C. Koehler, W. Jaro, M. Hanefeld (2002)
Subclinical inflammation is strongly related to insulin resistance but not to impaired insulin secretion in a high risk population for diabetes.Metabolism: clinical and experimental, 51 6
R. Bellis, E. Novoa, B. Dol, J. Cazerez, Gerardo Rivera-Arroyo, B. Balbela, A. Navarro (1984)
Changes in platelet aggregation caused by glyburide in diabetic patients.Clinical therapeutics, 6 3
M.I. Freed, R. Ratner, S.M. Marcovina (2002)
Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus: Rosiglitazone Study 108 InvestigatorsAm J Cardiol, 90
E. Velazquez, E. Velazquez, S. Mendoza, S. Mendoza, Ping Wang, Ping Wang, C. Glueck, C. Glueck (1997)
Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome.Metabolism: clinical and experimental, 46 4
M. Supiano, R. Hogikyan, L. Morrow, F. Ortiz-Alonso, W. Herman, R. Bergman, J. Halter (1992)
Hypertension and insulin resistance: role of sympathetic nervous system activity.The American journal of physiology, 263 5 Pt 1
P. Dandona, A. Aljada, P. Mohanty, H. Ghanim, Wael Hamouda, E. Assian, Shakeel Ahmad (2001)
Insulin Inhibits Intranuclear Nuclear Factor κB and Stimulates IκB in Mononuclear Cells in Obese Subjects: Evidence for an Anti-inflammatory Effect?The Journal of Clinical Endocrinology and Metabolism, 86
B. Sung, J. Izzo, P. Dandona, Michael Wilson (1999)
Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus.Hypertension, 34 1
D. Nagi, J. Yudkin (1993)
Effects of Metformin on Insulin Resistance, Risk Factors for Cardiovascular Disease, and Plasminogen Activator Inhibitor in NIDDM Subjects: A study of two ethnic groupsDiabetes Care, 16
P. Dandona, A. Aljada, P. Mohanty (2002)
The anti-inflammatory and potential anti-atherogenic effect of insulin: a new paradigmDiabetologia, 45
P. Palumbo (1998)
Metformin: Effects on CardiovascularRisk Factors in Patients withNon–Insulin-Dependent Diabetes MellitusJournal of Diabetes and Its Complications, 12
K. Lam, S. Tiu, M. Tsang, T. Ip, S. Tam (1998)
Acarbose in NIDDM Patients With Poor Control on Conventional Oral Agents: A 24-week placebo-controlled studyDiabetes Care, 21
M. Bayraktar, D. Thiel, N. Adalar (1996)
A Comparison of Acarbose Versus Metformin as an Adjuvant Therapy in Sulfonylurea-Treated NIDDM PatientsDiabetes Care, 19
Y. Nagai, T. Abe, G. Nomura (2001)
Does pioglitazone, like troglitazone, increase serum levels of lipoprotein(a) in diabetic patients?Diabetes care, 24 2
C. Agardh, P. Bjorgell, P. Nilsson‐Ehle (1999)
The effects of tolbutamide on lipoproteins, lipoprotein lipase and hormone-sensitive lipase.Diabetes research and clinical practice, 46 2
D. Kelley, P. Bidot, Z. Freedman, B. Haag, D. Podlecki, M. Rendell, D. Schimel, S. Weiss, T. Taylor, A. Krol, J. Magner (1998)
Efficacy and Safety of Acarbose in Insulin-Treated Patients With Type 2 DiabetesDiabetes Care, 21
A. Panahloo, V. Mohamed-ali, Christine Andrès, A. Denver, John Yudkin (1998)
Effect of insulin versus sulfonylurea therapy on cardiovascular risk factors and fibrinolysis in type II diabetes.Metabolism: clinical and experimental, 47 6
M. Hanefeld, S. Fischer, J. Schulze, M. Spengler, M. Wargenau, K. Schollberg, K. Fücker (1991)
Therapeutic Potentials of Acarbose as First-Line Drug in NIDDM Insufficiently Treated With Diet AloneDiabetes Care, 14
J. May, Z. Qu (2000)
Troglitazone protects human erythrocytes from oxidant damage.Antioxidants & redox signaling, 2 2
R. DeFronzo, A. Goodman (1995)
Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.The New England journal of medicine, 333 9
J. Steinberg (1989)
Book ReviewAmbulatory Pediatric CareThe New England Journal of Medicine, 320
J. Sowers, M. Epstein, E. Frohlich (2001)
Diabetes, Hypertension, and Cardiovascular Disease: An UpdateHypertension: Journal of the American Heart Association, 37
(1998)
Consensus development conference on insulin resistanceDiabetes Care, 21
J. Levy, M. Vandenberg, G. Grunberger (1995)
Insulin versus glipizide treatment in patients with non-insulin-dependent diabetes mellitus. Effects on blood pressure and glucose tolerance.American journal of hypertension, 8 5 Pt 1
D. Siluk, R. Kaliszan, P. Haber, J. Petrusewicz, Z. Brzozowski, G. Sut (2002)
Antiaggregatory activity of hypoglycaemic sulphonylureasDiabetologia, 45
L. Ryysy, Hannele Yki-Järvinen (2001)
Improvement of glycemic control by 1 year of insulin therapy leads to a sustained decrease in sE-selectin concentrations in type 2 diabetes.Diabetes care, 24 3
S. Aronoff, S. Rosenblatt, S. Braithwaite, J. Egan, A. Mathisen, R. Schneider (2000)
Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.Diabetes care, 23 11
H. Ghanim, R. Garg, A. Aljada (2001)
Suppression of nuclear factor-κB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatheros-clerotic effect in the obeseJ Clin Endocrinol Metab, 86
R. Marfella, R. Acampora, G. Verrazzo, P. Ziccardi, N. Rosa, R. Giunta, D. Giugliano (1996)
Metformin Improves Hemodynamic and Rheological Responses to L-Arginine in NIDDM PatientsDiabetes Care, 19
D. Kirpichnikov, Samy McFarlane, J. Sowers (2002)
Metformin: An UpdateAnnals of Internal Medicine, 137
P. Raskin, E. Rappaport, S. Cole, Y. Yan, R. Patwardhan, M. Freed (2000)
Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with Type II diabetesDiabetologia, 43
F. Escobar-Jiménez, C. Barajas, A. Leiva, F. Cano, Ramón Masoliver, J. Herrera-Pombo, A. Hernández-Mijares, F. Piñon, H. Calle, J. Tébar, J. Soler, A. Cobos, E. Guardiola (1995)
Efficacy and tolerability of miglitol in the treatment of patients with non-insulin-dependent diabetes mellitusCurrent Therapeutic Research-clinical and Experimental, 56
A. Ceriello, C. Taboga, L. Tonutti, R. Giacomello, L. Stel, E. Motz, M. Pirisi (1996)
Post-meal coagulation activation in diabetes mellitus: the effect of acarboseDiabetologia, 39
K. Mather, S. Verma, T. Anderson (2001)
Improved endothelial function with metformin in type 2 diabetes mellitus.Journal of the American College of Cardiology, 37 5
B. Lindahl, T. Nilsson, J. Jansson, Kjell Asplund, G. Hallmans (1999)
Improved fibrinolysis by intense lifestyle intervention. A randomized trial in subjects with impaired glucose toleranceJournal of Internal Medicine, 246
K. Mather, T. Anderson, S. Verma (2001)
Insulin Action in the Vasculature: Physiology and PathophysiologyJournal of Vascular Research, 38
J.R. Sowers, M. Epstein, E.D. Frohlich (2001)
Diabetes, hypertension, and cardiovascular disease: an update [published erratum appears in Hypertension 2001 May; 37 (5): 1350]Hypertension, 37
L. Cominacini, M. Young, A. Capriati, U. Garbin, A. Pasini, M. Campagnola, A. Davoli, A. Rigoni, G. Contessi, V. Cascio (1997)
Troglitazone increases the resistance of low density lipoprotein to oxidation in healthy volunteersDiabetologia, 40
L. Howes, P. Sundaresan, D. Lykos (1996)
CARDIOVASCULAR EFFECTS OF ORAL HYPOGLYCAEMIC DRUGSClinical and Experimental Pharmacology and Physiology, 23
A. Wright, C. Cull, R. Holman, R. Turner (1998)
UKPDS 28: A Randomized Trial of Efficacy of Early Addition of Metformin in Sulfonylurea-Treated Type 2 DiabetesDiabetes Care, 21
N.V. Chu, A.P. Kong, D.D. Kim (2002)
Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes [published erratum appears in Diabetes Care 2002 May; 25 (5): 947]Diabetes Care, 25
B. Goldstein (2002)
Insulin resistance as the core defect in type 2 diabetes mellitus.The American journal of cardiology, 90 5A
F. Ovalle, D. Bell (1999)
Troglitazone's effect on lipoprotein(a) levels.Diabetes care, 22 5
R. Turner, R. Holman (1998)
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.BMJ
D. Steinberg, S. Parthasarathy, T. Carew, J. Khoo, J. Witztum (1989)
Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity.The New England journal of medicine, 320 14
J. Beckman, M. Creager, P. Libby (2002)
Diabetes and atherosclerosis: epidemiology, pathophysiology, and management.JAMA, 287 19
J. Hoffmann, M. Spengler (1997)
Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study.The American journal of medicine, 103 6
M. Charles, E. Eschwège, P. Grandmottet, Françoise Isnard, J. Cohen, J. Bensoussan, Hervé Berche, O. Chapiro, P. André, P. Vague, I. Juhan-vague, J. Bard, Michel Safar (2000)
Treatment with metformin of non‐diabetic men with hypertension, hypertriglyceridaemia and central fat distribution: the BIGPRO 1.2 trialDiabetes/Metabolism Research and Reviews, 16
G. Fanghänel, L. Sánchez-Reyes, Cesar Trujillo, D. Sotres, J. Espinosa-Campos (1996)
Metformin's Effects on Glucose and Lipid Metabolism in Patients with Secondary Failure to SulfonylureasDiabetes Care, 19
J. Rosenstock, D. Einhorn, K. Hershon (2002)
Efficacy and safety of pioglitazone in type 2 diabetes: a randomized, placebo-controlled study in patients receiving stable insulin therapy: the Pioglitazone 014 Study GroupInt J Clin Pract, 56
A. Vinik, T. Erbas, Tae Park, R. Nolan, G. Pittenger (2001)
Platelet dysfunction in type 2 diabetes.Diabetes care, 24 8
V. Fonseca, Tammy Reynolds, Donna Hemphill, C. Randolph, Jannaya Wall, Thomas Valiquet, J. Graveline, L. Fink (1998)
Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus.Journal of diabetes and its complications, 12 4
N. Pannacciulli, V. Mitrio, R. Marino, R. Giorgino, G. Pergola (2002)
Effect of glucose tolerance status on PAI-1 plasma levels in overweight and obese subjects.Obesity research, 10 8
A. Robinson, J. Burke, S. Robinson, D. Johnston, R. Elkeles (1998)
The Effects of Metformin on Glycemic Control and Serum Lipids in Insulin-Treated NIDDM Patients With Suboptimal Metabolic ControlDiabetes Care, 21
John Yudkin, A. Panahloo, C. Stehouwer, J. Emeis, Karen Bulmer, V. Mohamed-ali, A. Denver (2000)
The influence of improved glycaemic control with insulin and sulphonylureas on acute phase and endothelial markers in Type II Diabetic subjectsDiabetologia, 43
M. Sutton, M. Rendell, P. Dandona, J. Dole, K. Murphy, R. Patwardhan, J. Patel, M. Freed (2002)
A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes.Diabetes care, 25 11
Ken Kato, D. Yamada, S. Midorikawa, W. Sato, Tsuyoshi Watanabe (2000)
Improvement by the insulin-sensitizing agent, troglitazone, of abnormal fibrinolysis in type 2 diabetes mellitus.Metabolism: clinical and experimental, 49 5
O. Snorgaard, Lars Køber, J. Carlsen (1997)
The effect of metformin on blood pressure and metabolism in nondiabetic hypertensive patientsJournal of Internal Medicine, 242
H. Steinberg, G. Brechtel, A. Johnson, N. Fineberg, A. Baron (1994)
Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release.The Journal of clinical investigation, 94 3
D. Pavlović, R. Kocić, G. Kocić, T. Jevtović, S. Radenković, D. Mikić, M. Stojanovic, P. Djordjević (2000)
Effect of four‐week metformin treatment on plasma and erythrocyte antioxidative defense enzymes in newly diagnosed obese patients with type 2 diabetesDiabetes, 2
L. Klaff, L. Kernoff, A. Vinik, W. Jackson, P. Jacobs (1981)
Sulfonylureas and platelet function.The American journal of medicine, 70 3
D. Giugliano, N. Rosa, Giosué Maro, R. Marfella, R. Acampora, R. Buoninconti, F. D'onofrio (1993)
Metformin Improves Glucose, Lipid Metabolism, and Reduces Blood Pressure in Hypertensive, Obese WomenDiabetes Care, 16
G. Reaven, Ydi Chen, J. Jeppesen, P. Maheux, R. Krauss (1993)
Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles.The Journal of clinical investigation, 92 1
P. Grant (1996)
The Effects of High- and Medium-Dose Metformin Therapy on Cardiovascular Risk Factors in Patients With Type II DiabetesDiabetes Care, 19
S. Aronoff, S. Rosenblatt, S. Braithwaite (2000)
Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response studyDiabetes Care, 23
C. Cardillo, C. Kilcoyne, R. Cannon, J. Panza (2000)
Interactions between nitric oxide and endothelin in the regulation of vascular tone of human resistance vessels in vivo.Hypertension, 35 6
T. Tankova, D. Koev, L. Dakovska, G. Kirilov (2003)
The effect of repaglinide on insulin secretion and oxidative stress in type 2 diabetic patients.Diabetes research and clinical practice, 59 1
H. Lebovitz, J. Dole, R. Patwardhan, E. Rappaport, M. Freed (2001)
Rosiglitazone monotherapy is effective in patients with type 2 diabetes.The Journal of clinical endocrinology and metabolism, 86 1
R. Coniff, J. Shapiro, T. Seaton, George Bray (1995)
Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus.The American journal of medicine, 98 5
D. Ehrmann, D. Schneider, B. Sobel, M. Cavaghan, J. Imperial, R. Rosenfield, K. Polonsky (1997)
Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome.The Journal of clinical endocrinology and metabolism, 82 7
Patients with type 2 diabetes mellitus have a greater risk of cardiovascular disease than nondiabetic individuals. These patients are often insulin resistant and have an associated clustering of risk factors that contribute to cardiovascular disease. The risk factors include dyslipidemia, hypertension, altered hemostasis, and chronic inflammation. A primary objective in the management of type 2 diabetes mellitus is normalization of blood glucose levels; however, some of the oral drugs used to control blood glucose levels have significant effects on these risk factors. In this article, we review the current data involving the modification of these cardiovascular risk factors by the biguanide (metformin), the thiazolidinediones (troglitazone, rosiglitazone, and pioglitazone), the α-glucosidase inhibitors (miglitol, acarbose), and the insulin secretagogs (glyburide [glibenclamide], glipizide, chlorpropamide, tolbutamide, tolazamide, glimepiride, repaglinide, and nateglinide). Generally, the thiazolidinediones improve hemostasis and endothelial function and reduce blood pressure, while having variable effects on dyslipidemia. Metformin improves dyslipidemia and altered hemostasis and decreases plasma C-reactive protein levels with little or no effect on blood pressure. Data on the effects of the α-glucosidase inhibitors and insulin secretagogs are sparse; however, these drugs appear to have little or no effect on cardiovascular risk factors.
American Journal of Cardiovascular Drugs – Springer Journals
Published: Sep 11, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.